Khaled Alsheebani, a patient from the United Arab Emirates, traveled to The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) for a gene therapy treatment targeting sickle cell disease. Despite language barriers, Alsheebani understood the positive updates from his care team as he underwent the therapy.
Marcos de Lima, MD, who directs the Blood and Marrow Transplant and Cellular Therapy programs at OSUCCC – James and holds the William Greenville Pace III Endowed Chair in Cancer Research at Ohio State College of Medicine, described the impact of this new treatment. “A few years ago, if you would have asked me if this was possible, I would have said you’re dreaming,” says Marcos de Lima, MD.
Dr. de Lima further commented on Alsheebani’s progress: “This is truly revolutionary. All indications are that he’s effectively cured,” says Marcos de Lima, MD.
Gene therapies for sickle cell anemia are emerging as a significant development in treating blood disorders. The OSUCCC – James treats all forms of these conditions and is among institutions offering advanced therapies for patients worldwide.
